CClinicalTrials.gg
CompletedNCT04356378CAPACoV19Updated Jun 4, 2024

Long Term Physical Functional Limitations in Daily Living in SARS-CoV2 Infected Patients Hospitalized in the Acute Phase Then Requiring Rehabilitation

An observational study in Infection With Coronavirus SARS-CoV2, sponsored by CHU de Reims. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-06-04.

Sponsored by CHU de Reims · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
149
Ages
18 Years and older
Sex
All
01

Study summary

Infection with coronavirus SARS-CoV2 (COVID-19 disease) is unique with its speed of propagation, structural medical reorganizations and length of stay in intensive care needed, diversity of the affected population (in particular between young persons or fragile subjects), and impact on physical and mental health generated by confinement of populations.

Fatigue is a major component of COVID-19. Global muscular weakness is related to immobility, inflammation, corticosteroids treatment, hypoxemia due to pulmonary and/or cardiac infectious attacks and undernutrition suggests major physical functional repercussions. Thus, patients affected by COVID-19 with acute hospital management require sometimes complex rehabilitation management.

Retrospective studies on physical functional capacities in patients infected with SARS CoV1 showed long term physical activity limitations.

Read the detailed description

The aim of this study is to study factors associated with physical functional limitations in daily living in patients SARS-CoV2 infected and hospitalized in the acute phase then requiring rehabilitation.

02

Conditions studied

  • Infection With Coronavirus SARS-CoV2

Keywords

  • observational study
  • cohort study
  • coronavirus infections
  • respiratory distress syndrome
  • adult
  • rehabilitation
  • physical functional performance
  • long term care
  • exercise tolerance
  • clinical study
03

In context

Coronavirus Infections

928 studies on the registry are indexed under Coronavirus Infections; 49 are open to participants now.

This study's enrollment of 149 is below the median of 300 across 334 observational studies indexed under Coronavirus Infections.

Browse Coronavirus Infections studies →

Lead sponsor

CHU de Reims is the lead sponsor of 267 studies on the registry; 50 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

SARS-CoV2 infected patients, hospitalized in the acute phase then requiring rehabilitation follow-up.

Inclusion criteria

  • patient infected with SARS-CoV2
  • in-patient hospitalization in the acute phase because SARS-CoV2 infection
  • patient requiring rehabilitation after SARS-CoV2 infection acute phase
  • patient adult, aged more than 18 years old
  • patient accepting to participate in the study

Exclusion criteria

Exclusion criteria :

  • patient with cognitive disorder (Folstein Mini-Mental State Examination less than 22 on 30 points)
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
149 participants (actual)
Patient registry
No

Groups and cohorts

  • "infection with coronavirus SARS-CoV2" group

    "SARS-CoV2 infected patients" group: in-patient in the acute phase then requiring rehabilitation.

    Other: Data record

Interventions

  • OtherData record

    Data record

06

What researchers measure

Primary outcomes

  1. Physical functional limitations

    Physical functional limitations evaluated using 'sit to stand' test. The patient, seated in a chair without armrest, his arms crossed over his shoulders, should get up and sit down without help of the upper limbs as many times as possible in one minute.

    Time frame: 12 months

07

Study locations

1 site
  • Damien JOLLY
    Reims, France
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 4, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04356378
Lead sponsor
CHU de Reims
Responsible party
Sponsor
First posted
Apr 22, 2020
Start date
Jun 2, 2020
Primary completion
Aug 20, 2021
Completion
Jan 20, 2022
Last update
Jun 4, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion